Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice to see some upward movement! Not sure if something has leaked, or the chart finally broke out from the pressure building the last month. Or maybe its just the push toward earnings. Regardless, it is long overdue. This thing is so undervalued!
Great! Will check out the videos. Welcome to the board!
Haha!
We are also helping with the PGA! ---- Article:
USGA Calls NEP’s NCP14 Unit Home for U.S. Open World-Feed Production
COVID postponement, new rightsholder complicate the event
By Ken Kerschbaumer, Editorial Director
Friday, September 18, 2020 - 1:05 pm
Print This Story | Subscribe
More than 190 countries will broadcast the U.S. Open via a world feed produced by the USGA out of NEP’s NCP14 production unit.
“We take about 80% of the NBC feed,” explains Kevin Landy, senior director, broadcasting and production, USGA, “and then, when they go to commercial or to a feature that doesn’t translate for our international audience, we have our producer and director use one of our four cameras. Our unilateral cameras are on the 9th hole, which is a finishing hole on Thursday and Friday, and then on 16, 17, and 18.”
Shane Bacon is handling lead play-by-play for the world feed, and Ned Michaels is analyst.
It has been a unique Open for the USGA. Not only is there the pandemic to deal with and the tournament is being played in September instead of June, but, at the end of June, NBC Sports took over the USGA rights deal from Fox Sports.
NEP’s NCP14 production unit is at the center of the USGA U.S. Open world-feed production.
“Nobody saw that coming except for the guys orchestrating it,” says Landy. “And that plus the shift from June to September meant that Program Productions [Inc.] had to come through for us as there are many more sports being played now than when we usually have the Open in June. PPI was really good to us, making sure that key personnel we would have used in June were available in September. They have been great partners for the USGA production staff.”
Landy also credits NEP, which similarly finds many more of its facilities in use in September than in June.
“When the postponement happened in March,” says Landy, “one of the concerns was the availability of trucks, given the crush of college football and everything else. But NEP was able to get us a world-feed truck that gives us everything we need.”
The Open is being hosted in the New York City Tri-State area, and Landy says that has made a difference when it comes to crewing and the need for backup personnel.
“We have two EVS operators and also one standing by,” Landy notes, “but we are blessed to be in the New York City market because it is a large market and, if we needed to, we could draw replacements if needed. We don’t need backup crew hunkered in a hotel.”
Also helping out is Vault COVID-19 spit testing, which everyone onsite is required to do prior to arrival. Onsite, an additional BioReference Labs nasal-swab test is administered, and personnel then wait up to 24 hours for the results before going about their job.
“It has worked really well,” says Landy. “Also, PPI knows a lot of the protocols and is aware of what we are trying to accomplish, and it has been so far, so good.”
This is a triple-witching Friday. Options will not be a factor in the near term. Looking Strong now, btw.
This thing steadily climbs between now and earnings. Pertinent news accelerates that, its all coming together now.
Outstanding Find!! Adding when I can. No what you own folks!!
ECOR nice move.
Barrington Stick to Their Buy Rating for Opko Health Inc
8 hours ago (Sep 15, 2020 05:45PM ET)
Barrington analyst Michael Petusky maintained a Buy rating on Opko Health (NASDAQ:OPK) Inc on Tuesday, setting a price target of $7, which is approximately 120.82% above the present share price of $3.17.
Petusky expects Opko Health Inc to post earnings per share (EPS) of $0.05 for the third quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Opko Health, with an average price target of $8.
The analysts price targets range from a high of $10 to a low of $6.5.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $301.21 million and a net profit of $28.29 million. The company's market cap is $2.12 billion.
According to TipRanks.com, Barrington analyst Michael Petusky is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 4.0% and a 48.62% success rate.
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Barrington Stick to Their Buy Rating for Opko Health Inc
Add a Comment
"Based on 4 analysts offering 12 month price targets for Opko Health in the last 3 months. The average price target is $8.00 with a high forecast of $10.00 and a low forecast of $6.50. The average price target represents a 153.97% increase from the last price of $3.15".....Tip Ranks
Lol, sure, whatever.
Wow! Lit up at $3.20 right at close of A/H. Seems like someone is expecting good things from the conference.
They said they have never dealt with Colorado before and didn't know.
Nice $75,000 buy there!! 24,000 @ $3.13
Nice day so far. Lots of buying.
Good Morning all.
Great! Thank You!
Augusta, volunteering to help clear the board of people who can't follow the rules and insist on posting pinks and bb here.
Yes!! Myself and people from another site have been on it all weekend!
OPK up almost 9%, +.26 on a down day with sector weakness.
Femto, thanks for all of your work this weekend. Not sure what the short term share price rise will be (There will be some), but it is much appreciated. Let's get it to $4 and higher this week!! Bye-Bye shorts!!
BOOM!!! Vifor CEO: 2021 will be more of a launch year than a transition year
The CEO of the group Vifor Stefan Schulze also expects income from out-licensing in the second half of the year.
08/16/2020 17:51
Packaging line at Vifor Pharma in Geneva.
Packaging line at Vifor Pharma in Geneva.
The coming year 2021 will not be a transition year, but rather a "launch year", as he said in an interview with "Finanz und Wirtschaft" (edition 15.08.).
"We will launch several products next year and the year after that," emphasizes the Vifor boss. It will be Rayaldee and Korsuva in the US next year when approval is granted. In addition, the launches of Avacopan and CR845 in Europe are being prepared. The sale of Vadadustat to Fresenius Medical Care dialysis clinics in the USA is expected to start in 2022 . "We are introducing significant changes to our product portfolio. We are entering the market with four new products that will have a significant impact on long-term growth."
There were three reasons that the company lowered its annual forecast. The corona crisis affected the sales development of Ferninject and Veltassa. As a second reason, Schulze refers to the currency impact of the strong franc. And thirdly, there were challenges in Veltassa's sales. "If we factor out the corona effects, we have exceeded our growth targets in the first half of the year. If we continue with the measures, growth will return in the second half of the year," he is convinced.
Underestimated by Valtessa
At Valtessa, they clearly miscalculated, said Schulze. "We have a competitor who is not contributing to the growth of the overall market to the extent we had hoped. He is investing primarily to gain market share." In addition, the corona crisis had an effect. Fewer people went to the doctor and fewer patients started taking Valtessa.
Schulze also expects high "other income" from local out-licensing in the second half of the year. "For example, we have planned to out-license Veltassa in China. We are also looking for partners in regions where we are not represented for other products. Such contracts usually include advance payments."
Larger acquisitions are currently not in focus. It was decided to integrate Relypsa first. It's different with partnerships. With license agreements you have a "sweet spot". Schulze refers to the agreements with Chemocentryx for Avacopan, OPKO for Rayaldee or with Cara Therapeutics for Korsuva / CR845.
$3.50 Not out of the question for sure.
Agreed. Many folks on Twitter and others going to start positions on Tuesday.
OPK, Shorts have really hurt it this past month. Would be nice to give them the squeeze they deserve.
Wall Street Journal story ABOUT OPK!!! Should put some eyes on it come Tuesday.
https://www.msn.com/en-us/health/medical/labs-struggled-with-surge-in-covid-testing-demand-how-one-made-it-through/ar-BB18LkJi?li=BBnb7Kz
Wow! Wall Street Journal article on BRL. Great exposure! Ready for Tuesday!!
https://www.msn.com/en-us/health/medical/labs-struggled-with-surge-in-covid-testing-demand-how-one-made-it-through/ar-BB18LkJi?li=BBnb7Kz
No pinks/otb bb here please.
I know. It turned when the market turned at the end of the day.
Let's close green today. Reversal is in imo.
Somebody, or multiple people/entities wanting in the last couple of hours. Ready to see next week already!
"Since the program's launch BRL has successfully scheduled over 100,000 appointments and reduced the length of the testing process by around 50 percent."
"As part of the next phase, and connected with the goal of easing coronavirus restrictions, BioReference has begun to use Skedulo to assist the MLS, NBA and NFL with their player testing. As a further extension, the Mass Transit Authority (MTA) in New York has started to used BRL to help get the city moving again."
Added more today. I believe its only up from here.
Lol, you are absolutely right.